Effectiveness of simvastatin in the treatment of acute myocardial infarction
吕蓓,胡春燕,陆国平,龚兰生
DOI: https://doi.org/10.3969/j.issn.1001-1439.2002.12.005
2002-01-01
Journal of Clinical Cardiology
Abstract:Objective:To evaluate efficacy of simvastatin treatment in patients with AMI.Methods:One hundred and seventy six patients with AMI and normocholesterolemia who received thrombolysis, antiplatelet, anticoagulant, antianginal and PCI therapies were divided into two groups: simvastatin group consisted of 101 patients who received simvastatin 20 mg/d lasting at last 12 week and no simvastatin group consisted of 75 patients.The ocurrences of death, recurrent AMI, angina, repeat PCI, CABG and readmission were assessed during one year.Results:The incidence of death in one month was lower in the simvastatin group than in the no simvastatin group ( 4.95 % vs 14.67 %, P 0.05 ), The composite endpoint of death or recurrent AMI ( 10.89 % vs 22.67 %, P 0.05 ), angina pectoris ( 13.86 % vs 27.02 % ,P 0.05 ), repeat PCI or CABG( 8.90 % vs 21.33 %, P 0.05 ) and readmission ( 14.85 % vs 28.00 %, P 0.05 ) in one year were lower in the simvastatin group than in the no simvastatin group. Old age, LAD disease, extensive anterior MI had positive relationship with the composite and point death, recurrent AMI or angina pectoris; but LVEF, ACEI, simvastatin or PCI therapies had negtive relationship with the composite endpiont of death, recurrent AMI or angina pectoris.Conclusion:Simvastatin associated with antiplatelet, anticoagulant, antiischemic and PCI therapies significantly decrease the incidence of adverse cardiac events in patients with AMI and normocholesterolemia in one year.